Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

    ... syndromes (MDS) require transfusions at the risk of iron overload and associated organ damage, and death. Emerging evidence ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Efficacy and safety of deferasirox in myelodysplastic syndromes

    ... damage due to accumulation of non- transferrin -bound iron with consequent increased oxidative stress. Iron chelation has been ... plasma iron, independently from the efficacy on iron overload . Deferasirox is a potent NF-kB inhibitor, tested in vivo and on ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

    ... evaluating the effects of deferasirox on liver iron concentration (LIC), labile plasma iron (LPI) and pharmacokinetics (PK) along with serum ferritin values ... syndromes (MDS) and evidence of iron overload . Twenty-four heavily transfused MDS patients were enrolled in a ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes

    ... the presence of abnormal sideroblasts characterized by iron overload in the mitochondria, called RS. Based on the high frequency of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. How we treat lower risk myelodysplastic syndromes.

    ... correction of anemia , alloimmunization, and organ iron overload (for which the role of iron chelation remains debated). Treatment ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Supportive care in severe and very severe aplastic anemia

    ... bacterial and viral infections, transfusion strategy and iron chelation and assess the evidence basis. In fact, many recommendations for ... events like alloimmunization to blood products and iron overload have a significant impact on the prognosis of AA patients and need ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

    ... 600 lower-risk MDS patients (pts) with transfusional iron overload . Clinical outcomes were compared between chelated and nonchelated ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Infections in myelodysplastic syndromes: a review

    ... T-, and NK-cell defects and the possible consequences of iron overload due to red blood cell transfusions. The advanced age of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes

    ... and quality of life (QoL), and are associated with iron overload , potentially leading to organ damage. QoL studies demonstrate that ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy

    ... syndromes (MDS) are at increased risk of iron overload due to ineffective erythropoiesis and chronic transfusion therapy. ...

    Research Article last updated 07/18/2018 - 8:41am.